Breast Cancer   

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...

Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?

Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?

Which agents would you select and for how long would you treat them?

What factors if any would influence your decision and what would your approach be? 

Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...